Prof. Dr. Erich Schlick

Prof. Dr. Erich Schlick

General Partner

Homo vitae commodatus non donatus est.

— Publilius Syrus (ca. 90 - 40 B.C.)


Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody.

Erich joined Wellington as an Investment Partner for Life Sciences in October 2005 and has since then been responsible for a number of successful European biotech and medtech companies of the likes of Symetis (acquired by Boston Scientific). Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head of 3i Healthcare Worldwide.

Prior to venture capital, Erich spent 15 years with BASF Pharma / Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for several products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for treatment of rheumatoid arthritis and other autoimmune diseases.

He studied medicine in Berlin, Mainz, Heidelberg and trained at the US National Cancer Institute, where he specialized in oncology and immunology. He holds a professorship of immune pharmacology at the University of Heidelberg.